Paul Weihe1, Susann Weihrauch-Blüher2. 1. Department of Pediatrics I/Pediatric Endocrinology, University Hospital of Halle-Wittenberg, Ernst-Grube-Strasse 40, 06120, Halle (Saale), Germany. 2. Department of Pediatrics I/Pediatric Endocrinology, University Hospital of Halle-Wittenberg, Ernst-Grube-Strasse 40, 06120, Halle (Saale), Germany. susann.weihrauch-blueher@uk-halle.de.
Abstract
PURPOSE OF REVIEW: This review summarizes our current understanding of the metabolic syndrome (MetS) in children and adolescents. Special emphasis is given towards diagnostic criteria and therapeutic options. RECENT FINDINGS: Consistent diagnostic criteria to define MetS in childhood and adolescence are not available to date. There is common agreement that the main features defining MetS include (1) disturbed glucose metabolism, (2) arterial hypertension, (3) dyslipidemia, and (4) abdominal obesity. However, settings of cut-off values are still heterogeneous in the pediatric population. Additional features that may define cardiometabolic risk, such as non-alcoholic fatty liver disease (NAFDL) or hyperuricemia, are not considered to date. Prevalence of childhood obesity has more than doubled since 1980, and 6-39% of obese children and adolescents already present with MetS, depending on the definition applied. There is common agreement that a consistent definition of MetS is urgently needed for children to identify those at risk as early as possible. Such definition criteria should consider age, gender, pubertal stage, or ethnicity. Additional features such as NAFDL or hyperuricemia should also be included in MetS criteria. Lifestyle modification is still the main basis to prevent or treat childhood obesity and MetS, as other therapeutic options (pharmacotherapy, bariatric surgery) are not available or not recommended for the majority of affected youngster.
PURPOSE OF REVIEW: This review summarizes our current understanding of the metabolic syndrome (MetS) in children and adolescents. Special emphasis is given towards diagnostic criteria and therapeutic options. RECENT FINDINGS: Consistent diagnostic criteria to define MetS in childhood and adolescence are not available to date. There is common agreement that the main features defining MetS include (1) disturbed glucose metabolism, (2) arterial hypertension, (3) dyslipidemia, and (4) abdominal obesity. However, settings of cut-off values are still heterogeneous in the pediatric population. Additional features that may define cardiometabolic risk, such as non-alcoholic fatty liver disease (NAFDL) or hyperuricemia, are not considered to date. Prevalence of childhood obesity has more than doubled since 1980, and 6-39% of obesechildren and adolescents already present with MetS, depending on the definition applied. There is common agreement that a consistent definition of MetS is urgently needed for children to identify those at risk as early as possible. Such definition criteria should consider age, gender, pubertal stage, or ethnicity. Additional features such as NAFDL or hyperuricemia should also be included in MetS criteria. Lifestyle modification is still the main basis to prevent or treat childhood obesity and MetS, as other therapeutic options (pharmacotherapy, bariatric surgery) are not available or not recommended for the majority of affected youngster.
Authors: Olga van der Baan-Slootweg; Marc A Benninga; Anita Beelen; Job van der Palen; Christine Tamminga-Smeulders; Jan G P Tijssen; Wim M C van Aalderen Journal: JAMA Pediatr Date: 2014-09 Impact factor: 16.193
Authors: Lise G Bjerregaard; Britt W Jensen; Lars Ängquist; Merete Osler; Thorkild I A Sørensen; Jennifer L Baker Journal: N Engl J Med Date: 2018-04-05 Impact factor: 91.245
Authors: Corinna Hawkes; Trenton G Smith; Jo Jewell; Jane Wardle; Ross A Hammond; Sharon Friel; Anne Marie Thow; Juliana Kain Journal: Lancet Date: 2015-02-19 Impact factor: 79.321
Authors: Valter Paulo Neves Miranda; Paulo Roberto Dos Santos Amorim; Ronaldo Rocha Bastos; Karina Lúcia Ribeiro Canabrava; Márcio Vidigal Miranda Júnior; Fernanda Rocha Faria; Sylvia do Carmo Castro Franceschini; Maria do Carmo Gouveia Peluzio; Silvia Eloiza Priore Journal: Mediators Inflamm Date: 2020-07-09 Impact factor: 4.711